Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborators:
Montefiore Medical Center
Children's Hospital of Philadelphia
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00582621
First received: December 21, 2007
Last updated: July 10, 2014
Last verified: July 2014

December 21, 2007
July 10, 2014
July 2000
December 2015   (final data collection date for primary outcome measure)
To establish a collection of DNA and frozen lymphocytes for the purpose of facilitating genetic laboratory investigations of familial lymphoid neoplasms. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00582621 on ClinicalTrials.gov Archive Site
To perform linkage and candidate gene studies on informative families for the purpose of identifying novel lymphoproliferative syndrome (LPS) predisposition genes. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease and/or, non-Hodgkin's lymphoma or a second cancer after Hodgkin's disease.

Not Provided
Observational
Observational Model: Family-Based
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood or alternatively, subjects may provide a saliva or buccal cell sample

Non-Probability Sample

Clinical Genetics Service at MSKCC or to the MSKCC outpatient clinics of the Lymphoma or Leukemia Services in the Department of Medicine.

  • Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Colon Cancer
  • Renal Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with lymphoma or lymphoproliferative disease accepted for referral to the Cancer Family Clinic of the Department of Human Genetics for genetic counseling, or to the MSKCC outpatient clinics of the Lymphoma or Leukemia Services in the Department of Medicine in consultation for treatment who are found on routine history or through a Family History Questionnaire (FHQ) (Appendix A) to have relatives or members of successive generations of the family affected with Hodgkin's disease, non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma or other lymphoproliferative disease. Patients with lymphoma, associated with colon and renal cancer will be eligible for DNA storage through this protocol. Family members or probands with Hodgkin's disease who are women who received therapeutic irradiation for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are also eligible for participation.
  • The criteria for eligibility are broad because the ascertainment by the computerized FHQ does not allow for resolution of different types of lymphoma or different types of leukemia. Patient recall of this information is also imprecise. More accurate family history information will be obtained upon contact of family members and diagnoses will be verified by obtaining pathologic documentation. The spectrum of familial lymphoproliferative syndromes (LPS) may include all types of lymphoma as well as chronic lymphocytic leukemia. This is an additional reason to have a broad eligibility. Subset analysis will be performed on specific types of lymphoid neoplasms. DNA of patients with a family history of lymphoma who have consented to protocol 93-102 ("Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers") will also be eligible for inclusion in this study.
  • Family members of probands including patients, sisters, brothers, halfbrothers and sisters, sons, daughters, grandparents, as well as aunts and uncles are also eligible. An effort will be made to ascertain all living affected and unaffected living relatives in the affected lineage. An emphasis will be on affected sibling pairs and both parents, if alive.
  • Also eligible for inclusion are up to 2000 anonymized familial lymphoma/leukemia samples from Montefiore Medical Center, with information on age of onset, gender, lymphoma or leukemia type, familial relationship, and year of sample collection. No PHI will be used and therefore these samples will be fully and permanently anonymized to MSKCC.
  • As this study involves research that presents no greater than minimal risk to children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible for participation. The assent of any minor should be obtained before the patient is enrolled into this study, as well as the consent of the legal guardian.

Exclusion Criteria:

  • N/A
Both
Not Provided
Yes
Contact: Kenneth Offit, MD 646-888-4050
United States
 
NCT00582621
00-069
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • Montefiore Medical Center
  • Children's Hospital of Philadelphia
Principal Investigator: Kenneth Offit, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP